A formal assessment by the National Institute for Health and Care Excellence (NICE) of whether a licensed medicine should be routinely funded and offered by the NHS in England, based on how well it works and whether it is good value for the NHS. A positive NICE technology appraisal is a separate step from MHRA licensing: a medicine can hold a UK marketing authorisation without yet being routinely available on the NHS for a given use, and the two decisions can happen on different timelines.
Peptides where this matters
Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.